Evidence map›Paper›PMID 34692203›Full record

ArticleBiomedical optics express2021

Rapid non-destructive volumetric tumor yield assessment in fresh lung core needle biopsies using polarization sensitive optical coherence tomography.

Sreyankar Nandy, Timothy L Helland, Benjamin W Roop, Rebecca A Raphaely, Amy Ly, Madelyn Lew, Sarita R Berigei, Martin Villiger, Anastasia Sorokina, Margit V Szabari and 3 more

Open access · goldAbstract read
In one paragraph

Article in Biomedical optics express, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Microscopic Small Airway Abnormalities Identified in Early Idiopathic Pulmonary FibrosisAmerican journal of respiratory and critical care medicine · 2024
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Reply to KalverdaAmerican journal of respiratory and critical care medicine · 2022
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Sreyankar NandyDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA 02110, USA.ORCID https://orcid.org/0000-0002-2553-7109
Timothy L HellandHarvard Medical School, Boston, MA 02110, USA.
Benjamin W RoopDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA 02110, USA.
Rebecca A RaphaelyDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA 02110, USA.
Amy LyWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02110, USA.
Madelyn LewDepartment of Pathology, University of Michigan, Ann Arbor, MI 48104, USA.
Sarita R BerigeiDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA 02110, USA.
Martin VilligerWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02110, USA.ORCID https://orcid.org/0000-0003-3819-1271
Anastasia SorokinaDepartment of Pathology, University of Illinois at Chicago, Chicago, IL 60131, USA.
Margit V SzabariDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA 02110, USA.
Florian J FintelmannHarvard Medical School, Boston, MA 02110, USA.
Melissa J SuterDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA 02110, USA.
Lida P HaririDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA 02110, USA.
Harvard University · USMassachusetts General Hospital · USUniversity of Illinois Chicago · USUniversity of Michigan · US

Funding

In vivo endobronchial OCT for IPF diagnosis and therapy response assessmentR01HL152075 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HARIRI, LIDA P · 2020 to 2024
$4.0M
Increasing the diagnostic yield of low-risk bronchial biopsy in the evaluation ofR01CA167827 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUMA, BRETT E, SUTER, MELISSA J · 2013 to 2017
$2.7M
Low risk in vivo diagnosis of IPF with optical imagingK23HL132120 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HARIRI, LIDA P · 2016 to 2020
$896k
NCI NIH HHS R01 CA167827NHLBI NIH HHS K23 HL132120NHLBI NIH HHS R01 HL152075
6 · The paper itself

Abstract

Adequate tumor yield in core-needle biopsy (CNB) specimens is essential in lung cancer for accurate histological diagnosis, molecular testing for therapeutic decision-making, and tumor biobanking for research. Insufficient tumor sampling in CNB is common, primarily due to inadvertent sampling of tumor-associated fibrosis or atelectatic lung, leading to repeat procedures and delayed diagnosis. Currently, there is no method for rapid, non-destructive intraprocedural assessment of CNBs. Polarization-sensitive optical coherence tomography (PS-OCT) is a high-resolution, volumetric imaging technique that has the potential to meet this clinical need. PS-OCT detects endogenous tissue properties, including birefringence from collagen, and degree of polarization uniformity (DOPU) indicative of tissue depolarization. Here, PS-OCT birefringence and DOPU measurements were used to quantify the amount of tumor, fibrosis, and normal lung parenchyma in 42 fresh, intact lung CNB specimens. PS-OCT results were compared to and validated against matched histology in a blinded assessment. Linear regression analysis showed strong correlations between PS-OCT and matched histology for quantification of tumors, fibrosis, and normal lung parenchyma in CNBs. PS-OCT distinguished CNBs with low tumor content from those with higher tumor content with high sensitivity and specificity. This study demonstrates the potential of PS-OCT as a method for rapid, non-destructive, label-free intra-procedural tumor yield assessment.

Identifiers

PMID34692203
PMCPMC8515979
OpenAlexW3188355000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.